> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# West Pharmaceutical Raises 2026 Profit Outlook To $9.38-$9.48 A Share As High-Value Components Jump 19.7%
- URL: https://www.bullished.co/west-pharmaceutical-raises-2026-profit-outlook-to-9-38-9-48-a-share-as-high-value-af17e470/
- Published: 2026-10-29T11:21:03.000Z
- Updated: 2026-10-29T11:21:03.000Z
- Description: West lifted its full-year sales and adjusted earnings guidance after third-quarter sales rose 8.7% to $874.5 million.
- Author: Matteo Parrino
- Tags: Earnings, WST, Industry: Healthcare

[West Pharmaceutical Services](https://www.bullished.co/tag/wst/), which makes containment and delivery systems for injectable drugs, raised its 2026 guidance for [adjusted earnings to $9.38-$9.48 a share](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000118/wst-20261029.htm?ref=bullished.co), up from $8.85-$9.05, after third-quarter results that CEO Michel Lagarde said exceeded the company's expectations. Net sales guidance rose to $3.41 billion-$3.42 billion from $3.345 billion-$3.380 billion.

## Components lead the quarter

Third-quarter [net sales reached $874.5 million](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000118/exh991q32026earningsrelease.htm?ref=bullished.co), up 8.7% from a year earlier and 11.9% organically. Diluted earnings per share rose 57.3% to $3.02, and adjusted earnings per share climbed 35.7% to $2.66.

Net income of $214.0 million included a [$55.7 million gain](https://www.prnewswire.com/news-releases/west-reports-third-quarter-2026-results-302922802.html?ref=bullished.co) on selling the SmartDose 3.5mL on-body delivery system to AbbVie, so the reported figure runs ahead of the underlying trend. Adjusted operating margin widened to 25.3% from 21.1%.

"Our results were again led by our High-Value Product (HVP) Components business," Lagarde said. That line [grew 19.7%](https://www.prnewswire.com/news-releases/west-reports-third-quarter-2026-results-302922802.html?ref=bullished.co) to $466.7 million and made up 53% of sales. Delivery devices were flat at $99.1 million, and standard products rose 2.9% to $163.0 million.

The West Vantage segment fell 7.3% to $145.7 million, which the company tied to the planned loss of a continuous glucose monitor customer. Management said that result was slightly better than expected.

## Buybacks and cash

West repurchased $231 million of stock in the quarter, bringing its total for the first nine months to $685 million. Operating cash flow for the nine months was $403 million, with capital spending of $125 million. Full-year capital spending guidance was cut to $215 million-$220 million from $250 million-$275 million.

The board also declared a fourth-quarter dividend of $0.26 a share, 18% above the $0.22 paid in the prior quarter.

## The business behind the numbers

West makes stoppers, seals, syringe and cartridge components, vials and self-injection devices for drug companies. Its Proprietary Products segment, which sells mainly to drugmakers, generated $728.8 million of third-quarter sales, up 12.6%.

For the fourth quarter, West guides to net sales of $820 million-$830 million and adjusted earnings per share of $2.22-$2.32, according to its [earnings presentation](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000118/a3q26earningsdeck-final.htm?ref=bullished.co). Organic sales growth guidance for the full year rose to 11.3%-11.6% from 10%-11%.

West expects no further SmartDose 3.5mL product sales for the rest of the year, after $11.8 million in the third quarter.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — WEST PHARMACEUTICAL SERVICES INC (WST)](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000118/wst-20261029.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit exh991q32026earningsrelease.htm — WEST PHARMACEUTICAL SERVICES INC 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000118/exh991q32026earningsrelease.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit a3q26earningsdeck-final.htm — WEST PHARMACEUTICAL SERVICES INC 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000118/a3q26earningsdeck-final.htm?ref=bullished.co) — SEC EDGAR
- [West Reports Third-Quarter 2026 Results](https://www.prnewswire.com/news-releases/west-reports-third-quarter-2026-results-302922802.html?ref=bullished.co) — prnewswire.com

### More on West Pharmaceutical

- [West Pharmaceutical Signs $950 Million Five-Year Credit Deal, Retiring Its 2019 Loan](https://www.bullished.co/west-pharmaceutical-signs-950-million-five-year-credit-deal-retiring-its-2019-loan-b681ffe6/)

[All West Pharmaceutical (WST) coverage →](https://www.bullished.co/tag/wst/)